Half-Year Report JANUARY - JUNE 2023 morphosys Group Interim Statement Contents MorphoSys Group: Half-Year Report January - June 2023 | | | | 5 | Interim Group Management Report | | --- | --- | | 5 | Operating Business Performance | | 13 | Strategy and Group Management | | 13 | Corporate Developments | | 13 | General Business and Market Environment | | 14 | Intellectual Property | | 14 | Human Resources | | 15 | Financial Analysis | | 20 | Interim Consolidated Financial Statements | | 20 | Consolidated Stat ...

First Quarter Interim Statement January – March 2023 2 Group Interim Statement Contents MorphoSys Group: First Quarter Interim Statement January – March 2023 3 Summary MorphoSys – I/2023 5 Group Interim Statement 5 Operating Business Performance 12 Human Resources 13 Financial Analysis 16 Subsequent Events 16 Financial Guidance 17 Group Interim Statement 17 Consolidated Statement of Profit or Loss (IFRS) – (unaudited) 18 Consolidated Balance Sheet (IFRS) – (unaudited) 20 Consolidated Statement of Changes in ...

Annual Report 2022 Our Clinical Pipeline | Clinical Programs Developed | | --- | | by Partners (Selection) | | | Most advanced | | | --- | --- | --- | | | development stage | | | | | LAUNCH | | Program Indication | | | | Tafasitamab L-MIND / Relapsed or refractory (r/r) | .. 02 . | | | diffuse large B-cell lymphoma (DLBCL) | | | | frontMIND / First-line DLBCL | . . . O | | | inMIND / r/r follicular lymphoma/ | ... O | | | marginal zone lymphoma | | | | B-MIND / r/r DLBCL | ... O | | | firstMIND / First-line ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ Form 20-F £ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR £ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...

Half-Year Report JANUARY - JUNE 2022 morphosys Group Interim Statement Contents MorphoSys Group: Half-Year Report January - June 2022 3 Summary | 5 | Interim Group Management Report | | --- | --- | | 5 | Operating Business Performance | | 14 | Strategy and Group Management | | 14 | Corporate Developments | | 14 | Subsequent Events | | 14 | General Business and Market Environment | | 15 | Intellectual Property | | 15 | Human Resources | | 16 | Financial Analysis | | 22 | Interim Consolidated Financial Statem ...

First Quarter Interim Statement JANUARY – MARCH 2022 2 Group Interim Statement Contents MorphoSys Group: First Quarter Interim Statement January – March 2022 3 Summary MorphoSys – I/2022 5 Group Interim Statement 5 Operating Business Performance 12 Human Resources 14 Financial Analysis 17 Subsequent Events 18 Financial Guidance 19 Group Interim Statement 19 Consolidated Statement of Profit or Loss (IFRS) – (unaudited) 20 Consolidated Balance Sheet (IFRS) – (unaudited) 22 Consolidated Statement of Changes in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ Form 20-F ___________________________ £ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR £ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

2 0 2 1 A n n u a l R e p o r t A n n u a l R e p o r t 2 0 2 1 Our Clinical Pipeline | | development stage | | --- | --- | | Program | | | Indication | | | Tafasitamab1 | | | L-MIND / Relapsed or refractory (r/r) | | | diffuse large B-cell lymphoma (DLBCL) | | | B-MIND / r/r DLBCL | | | firstMIND / First-line DLBCL | .00 0 | | frontMIND / First-line DLBCL | | | inMIND / r/r follicular lymphoma/ | | | marginal zone lymphoma | | | Pelabresib | | | MANIFEST-2 / Myelofibrosis | | | MANIFEST / Myelofibrosis | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...